{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:56:01Z","timestamp":1791510961539,"version":"4.3.4"},"reference-count":17,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014805","name":"Roche Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014805","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Hematology"],"published-print":{"date-parts":[[2022,1,27]]},"abstract":"<jats:p>Subcutaneous (SC) rituximab may be beneficial in terms of convenience and tolerability, with potentially fewer and less severe administration-related reactions (ARRs) compared to the intravenous (IV) form. This report presents the results of a phase IIIb study conducted in Italy. The study included adult patients with CD20+ DLBCL or FL having received at least one full dose of IV RTX 375\u2009mg\/m2 during induction or maintenance. Patients on induction received \u22654 cycles of RTX SC 1400\u2009mg plus standard chemotherapy and FL patients on maintenance received \u22656 cycles of RTX SC. Overall, 159 patients (73 DLBCL, 86 FL) were enrolled: 103 (54 DLBCL, 49 FL) completed induction and 42 patients with FL completed 12 maintenance cycles. ARRs were reported in 10 patients (6.3%), 3 (4.2%) with DLBCL and 7 (8.1%) with FL, all of mild severity, and resolved without dose delay\/discontinuation. Treatment-emergent adverse events (TEAEs) and serious adverse events occurred in 41 (25.9%) and 14 patients (8.9%), respectively. Two patients with DLBCL had fatal events: Klebsiella infection (related to rituximab) and septic shock (related to chemotherapy). Neutropenia (14 patients, 8.9%) was the most common treatment-related TEAE. Two patients with DLBCL (2.8%) and 6 with FL (7.0%) discontinued rituximab due to TEAEs. 65.2% and 69.7% of patients with DLBCL and 67.9% and 73.6% of patients with FL had complete response (CR) and CR unconfirmed, respectively. The median time to events (EFS, PFS, and OS) was not estimable due to the low rate of events. At a median follow-up of 29.5 and 47.8 months in patients with DLBCL and FL, respectively, EFS, PFS, and OS were 70.8%, 70.8%, and 80.6% in patients with DLBCL and 77.9%, 77.9%, and 95.3% in patients with FL, respectively. The switch from IV to SC rituximab in patients with DLBCL and FL was associated with low risk of ARRs and satisfactory response in both groups. This trial was registered with NCT01987505.<\/jats:p>","DOI":"10.1155\/2022\/5581772","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T17:35:29Z","timestamp":1643304929000},"page":"1-10","source":"Crossref","is-referenced-by-count":4,"title":["Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1017-6961","authenticated-orcid":true,"given":"Mario","family":"Petrini","sequence":"first","affiliation":[{"name":"Section of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Gaidano","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mengarelli","sequence":"additional","affiliation":[{"name":"Hematology Unit, Experimental and Clinical Oncology Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Consoli","sequence":"additional","affiliation":[{"name":"Division of Hematology, ARNAS Garibaldi, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Humanitas Clinical and Research Center-IRCCS, Humanitas Cancer Center, Rozzano, Milan, Italy"},{"name":"Humanitas University Pieve Emanuele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Liberati","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliera \u201cSanta Maria\u201d, Terni, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[{"name":"Hematology Division, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy"},{"name":"Department of Translational Medicine, University of Eastern Pedmont, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Fraticelli","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gemelli Molise, Campobasso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Guarini","sequence":"additional","affiliation":[{"name":"Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori \u2018Giovanni Paolo II\u2019, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Mannina","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda Ospedaliera, Papardo, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ferrando","sequence":"additional","affiliation":[{"name":"Medical Oncology, ASST Lecco, Lecco, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Instituto Nazionale dei Tumori, University of Milan, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[{"name":"Department of Emergency and Organ Transplantation \u201cAldo Moro\u201d, University School of Medicine and Unit of Hematology and Stem Cell Transplantation, AOU Consorziale Policlinico, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[{"name":"Division of Haematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Marino","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Oncology, Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Camera","sequence":"additional","affiliation":[{"name":"Hematology Unit, Sant\u2019Anna e San Sebastiano Hospital, Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Murineddu","sequence":"additional","affiliation":[{"name":"Hematology & Bone Marrow Transplant Unit, San Francesco Hospital, Nuoro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Battistini","sequence":"additional","affiliation":[{"name":"Hematology Unit, AO San Camillo Forlanini, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Caparrotti","sequence":"additional","affiliation":[{"name":"Department of Haematology, ASL Caserta (CE), Hospital Moscati, Aversa (CE), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Turrini","sequence":"additional","affiliation":[{"name":"Division of Hematology, Valduce Hospital, Como, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[{"name":"Division of Hematology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Santini","sequence":"additional","affiliation":[{"name":"ASL Toscana Centro, Department of Oncology, Oncoematology Unit, Santo Stefano Hospital, Prato, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Cerqueti","sequence":"additional","affiliation":[{"name":"General Medicine, Hospital of Macerata, Macerata, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres J. M.","family":"Ferreri","sequence":"additional","affiliation":[{"name":"Department of Onco-Haematology, Division of Experimental Oncology, IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Cantore","sequence":"additional","affiliation":[{"name":"Hematology and Hematopoietic Transplantation Unit, San G. Moscati Hospital, Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Inzoli","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ospedale Maggiore ASST, Crema, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cardinale","sequence":"additional","affiliation":[{"name":"Onco-hematology Unit, ARNAS Civico Di Cristina Benfratelli, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Ronci","sequence":"additional","affiliation":[{"name":"Hematology Unit, SS Filippo and Nicola Hospital, ASL1 Avezzano (AQ), Avezzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"La Nasa","sequence":"additional","affiliation":[{"name":"Department of Medical Science and Public Health, Hematology and Transplant Center, \u201cA. Businco\u201d Hospital, University of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Massimi","sequence":"additional","affiliation":[{"name":"Roche S. p. A., Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Gaglione","sequence":"additional","affiliation":[{"name":"Roche S. p. A., Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Barbiero","sequence":"additional","affiliation":[{"name":"Roche S. p. A., Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl498"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25460"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv018"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx128"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.008"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90276-3"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v83.2.435.bloodjournal832435"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1997.12.177"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70005-1"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.173583"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(17)30078-9"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.52.2631"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1349906"},{"key":"16"},{"issue":"5","key":"17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.16227","article-title":"Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study","volume":"188","author":"R. Garc\u00eda-Mu\u00f1oz","year":"2020","journal-title":"British Journal of Haematology"}],"container-title":["Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2022\/5581772.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2022\/5581772.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2022\/5581772.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T17:35:33Z","timestamp":1643304933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/ah\/2022\/5581772\/"}},"subtitle":[],"editor":[{"given":"Estella M.","family":"Matutes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":17,"alternative-id":["5581772","5581772"],"URL":"https:\/\/doi.org\/10.1155\/2022\/5581772","relation":{},"ISSN":["1687-9112","1687-9104"],"issn-type":[{"value":"1687-9112","type":"electronic"},{"value":"1687-9104","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}